

Supporting Information

Synthesis of Isoxazoline-*N*-oxides via [Hydroxy(tosyloxy)iodo]benzene (HTIB) Mediated Oxidative *N-O* Coupling

Mustafa J. Raihan, Veerababurao Kavala, Pateliya Mujjamil Habib, Qiao-Zhi Guan, Chun-Wei Kuo

*and Ching-Fa Yao**

Department of Chemistry, National Taiwan Normal University, 88, Sec. 4, Tingchow Road, Taipei,
Taiwan 116 R.O.C.

cheayaocf@ntnu.edu.tw

Table of Contents

1. General Information	iii
2. Experimental Procedures	iii
3. Spectral Data	vi
4. X-ray crystallographic structures	xvii
5. ^1H and ^{13}C NMR spectra of 1a-34	xxvi
6. Spectra related to the ^1H NMR experiment	lvii

1. General Information

Reagents and solvents were purchased from various commercial sources and were used directly without any further purification unless otherwise stated. Column chromatography was performed with 63-200 mesh silicagel. ^1H and ^{13}C NMR spectra were recorded at 400 and 100 MHz, respectively. Chemical shifts are reported in parts per million (δ) using TMS as an internal standard and coupling constants are expressed in hertz. IR spectra were recorded on an FT-IR spectrometer and are reported in cm^{-1} . Melting points were recorded using an electro thermal capillary melting point apparatus and are uncorrected. Sonication was conducted at 42 kHz with a power of 100W. The β -hydroxyketones were synthesized by following literature reports.^{r1, r2, r3} **26a** and **28a** are known compounds.^{3b,d,e}

2. Experimental Procedures

2.1. Representative procedure for preparation of oximes

Pyridine (4.5 mmol) was added to a stirred solution of β -hydroxyketone (3 mmol) and hydroxylamine hydrochloride (6 mmol) in 5 ml methanol at room temperature and the reaction was monitored by TLC. After the completion of the reaction, the solvent was evaporated in a vacuum. 5 ml of a 10% HCl solution was added and the white salt was dissolved in water. The organic compound was extracted with ethyl acetate (25 ml \times 3). The combined organic layer was washed with water and brine; dried over MgSO_4 , filtered and concentrated in a vacuum. The resulting residue was further purified by flash column chromatography.

2.2. Preparation of (6-(hydroxyimino)cyclohex-1-enyl)(2-nitrophenyl)methyl acetate (30)

To a stirred solution of 2-(hydroxy(2-nitrophenyl)methyl)cyclohex-2-enone (5 mmol) and acetic anhydride (20 mmol) in DCM (5 ml) was added 4,4-dimethylaminopyridine (10 mol%) and the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was added to ice cold water (50 ml) and the organic component was extracted with ethyl acetate (50 ml \times 3). The combined organic layer was washed with brine, dried over magnesium sulfate and concentrated in a vacuum. The

resulting residue was further purified by flash column chromatography to give pure (2-nitrophenyl)(6-oxocyclohex-1-enyl)methyl acetate. It was then treated with hydroxylamine hydrochloride in the presence of pyridine (See representative procedure for the preparation of oxime (section 2.1)).

2.3. General procedure for the oxidative N-O coupling.

Method A

To a 50 ml beaker containing the oxime derivative (0.5 mmol) in 5 ml of methanol was added [hydroxy(tosyloxy)iodo]benzene (0.55 mmol) in small portions with continuous stirring over a period of 25 min and the stirring was continued for an additional 5 min. An equal amount of water was then added. If the solid product precipitated out at the bottom of the beaker, the precipitate was filtered and washed with 60% methanol in water to give the pure product. In cases where the product did not precipitate, an additional 10 ml of water was added to the reaction mixture and the organic compound was isolated by extraction with ethyl acetate ($15\text{ ml} \times 3$). The combined organic layer was dried over magnesium sulfate and concentrated in a vacuum. The resulting residue was further purified by flash column chromatography.

Method B

To a 50 ml beaker containing the oxime derivative (0.5 mmol) in 5 ml of water was added [hydroxy(tosyloxy)iodo]benzene (0.55 mmol) in small portions with continuous stirring over a period of 45 min. After completion of the addition, the stirring was continued for an additional 5 min. The crude precipitated product was then isolated by filtration and washed with water. In the case of an oily product, the reaction mixture was extracted with ethyl acetate ($2 \times 10\text{ mL}$). The organic layer was separated, dried over magnesium sulfate and concentrated in a vacuum. The resulting residue was further purified by flash column chromatography.

2.4. Preparation of (2Z)-3-(methylimino)-2-(2-nitrobenzylidene)butanal (33)


To a stirred solution of 3-methyl-4-(2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (2 mmol) in 1.6 ml of DMSO was added triethylamine (4.4 mmol) and the reaction was monitored by TLC. After 0.5 h, the reaction mixture was transferred into 50 ml of water in a beaker and extracted with ethyl acetate (50ml × 3). The combined organic layer was washed with a brine solution (50 ml × 2), dried over magnesium sulfate and concentrated in a vacuum. The resulting residue was further purified by flash column chromatography. (15% EA in hexane).

2.5. Preparation of 3-(hydroxyimino)-2-(2-nitrobenzylidene)butylidene)-5,5-dimethylcyclohexane-1,3-dione (34)

To a 20 ml vial containing (2Z)-3-(methylimino)-2-(2-nitrobenzylidene)butanal (0.5 mmol) and 5,5-dimethyl-1,3-cyclohexanedione (0.6 mmol) was added 5ml of water, followed by stirring for 5 min. It was then sonicated for 18 h. The solid was isolated on a filter and the resulting residue was further purified by flash column chromatography.


3. Spectral Data

3-(2-nitrophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (1a).




A pale yellow solid; mp 156-158 °C; IR [KBr, cm⁻¹]: 3079, 2928, 2835, 1652, 1628, 1524, 1435, 1353, 1269, 1246, 1188, 1165; ¹H NMR (400 MHz, CDCl₃): δ 8.08 (d, *J* = 8.0 Hz, 1H), 7.75-7.69 (m, 2H), 7.57-7.51 (m, 1H), 6.80-6.79 (m, 1H), 5.87 (dd, *J* = 6.8, 4.4 Hz, 1H), 2.71-2.56 (m, 2H), 2.31-2.23 (m, 1H), 2.18-2.11 (m, 1H), 1.89-1.73 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 147.3, 136.2, 134.8, 134.5, 129.4, 128.2, 125.2, 123.2, 115.2, 75.3, 25.1, 21.2, 20.4; MS m/z (relative intensity): 261 (M⁺+1, 12), 260 (M⁺, 100), 231 (16), 214 (48), 197 (61), 182 (14), 168 (20), 158 (22); HRMS calcd for C₁₃H₁₂N₂O₄ (M⁺): 260.0792, found 260.0807; Anal. Calcd for C₁₃H₁₂N₂O₄: C, 60.00; H, 4.65; N, 10.76. Found: C, 59.96; H, 4.63; N, 10.72.

3-(2-nitro-5-chlorophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (2a).



A yellow solid; mp 172-174°C; IR [KBr, cm⁻¹]: 3099, 2947, 2864, 1656, 1628, 1527, 1343, 1270, 1256, 1183, 1110; ¹H NMR (400 MHz, CDCl₃): δ 8.09 (d, *J* = 8.8 Hz, 1H), 7.72 (d, *J* = 2.2 Hz, 1H), 7.48 (dd, *J* = 8.8, 2.3 Hz, 1H), 6.83 (dd, *J* = 5.6, 2.8 Hz, 1H), 5.88-5.85 (m, 1H), 2.71-2.58 (m, 2H), 2.31-2.18 (m, 1H), 2.18-2.11 (m, 1H), 1.87-1.76 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 145.4, 141.6, 136.9, 135.8, 129.7, 128.3, 126.9, 123.7, 114.9, 74.8, 25.2, 21.3, 20.4; MS m/z (relative intensity): 296 (M⁺+2, 23), 294 (M⁺, 83), 248 (100), 231 (73), 192 (26), 167 (18), 126 (8), 95 (4); HRMS calcd for C₁₃H₁₁ClN₂O₄ (M⁺): 294.0402, found 294.0416 and calcd for C₁₃H₁₁³⁷ClN₂O₄ (M⁺): 296.0372, found 296.0389.


3-(2,4-dichlorophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (3a).



A brown solid; mp 63-65 °C; IR [KBr, cm⁻¹]: 3070, 2945, 2834, 1657, 1624, 1587, 1561, 1472, 1451, 1381, 1355, 1263; ¹H NMR (400 MHz, CDCl₃): δ 7.44 (d, *J* = 1.8 Hz, 1H), 7.40 (d, *J* = 8.4 Hz, 1H), 7.30 (dd, *J* = 8.4, 1.8 Hz, 1H), 6.44 (d, *J* = 2.6 Hz, 1H), 5.80 (d, *J* = 2.4, 1H), 2.65-2.61 (m, 2H), 2.29-2.19 (m, 2H), 1.86-1.79 (m, 2H); ¹³C


NMR (100 MHz, CDCl₃): δ 136.4, 135.3, 135.0, 133.2, 129.9, 129.0, 128.0, 121.9, 115.6, 76.5, 24.9, 21.2, 20.5; MS m/z (relative intensity): 283 (M⁺, 100), 248 (17), 218 (5), 173 (13), 159 (2); HRMS calcd for C₁₃H₁₁³⁵Cl₂NO₂ (M⁺): 283.0161, found 283.0164 and calcd for C₁₃H₁₁Cl₁³⁷ClNO₂ (M⁺): 285.0132, found 285.0136.

3-(2-bromophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (4a).




A colorless solid; mp 93-95 °C; IR [KBr, cm⁻¹]: 3063, 2930, 2834, 1657, 1628, 1469, 1439, 1355, 1266; ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, *J* = 8.0 Hz, 1H), 7.44 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.36 (t, *J* = 7.7 Hz, 1H), 7.24-7.20 (m, 1H), 6.49 (dd, *J* = 5.8, 2.9 Hz, 1H), 5.84 (dd, *J* = 7.2, 4.4 Hz, 1H), 2.70-2.57 (m, 2H), 2.30-2.12 (m, 2H), 1.87-1.77 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 138.0, 136.7, 133.4, 130.4, 128.3, 128.2, 122.1, 121.8, 115.8, 79.1, 25.0, 21.2, 20.6; MS m/z (relative intensity): 296 (M⁺+3, 13), 293 (M⁺, 100), 215 (4), 214 (20), 183 (26), 156 (17); HRMS calcd for C₁₃H₁₂⁷⁹BrNO₂ (M⁺): 293.0046, found 293.0028; calcd for C₁₃H₁₂⁸¹BrNO₂ (M⁺): 295.0025, found 295.0004.

3-phenyl-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (5a).



A yellow gummy solid; IR [KBr, cm⁻¹]: 3063, 3033, 2945, 1653, 1631, 1451, 1355, 1266; ¹H NMR (400 MHz, CDCl₃): δ 7.43-7.35 (m, 5H), 6.02 (m, 1H), 5.60 (dd, *J* = 6.9, 4.3 Hz, 1H), 2.64 (t, *J* = 6.6 Hz, 2H), 2.31-2.14 (m, 2H), 1.91-1.80 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 138.3, 137.5, 129.1, 129.0, 126.9, 121.2, 116.2, 80.6, 24.9, 21.1, 20.7; MS m/z (relative intensity): 216 (M⁺+1, 45), 215 (M⁺, 100), 198 (9), 185 (5), 169 (22), 157 (14), 141 (22), 129 (10), 105 (33); HRMS calcd for C₁₃H₁₃NO₂ (M⁺): 215.0941, found 215.0948.


3-methyl-4-methylene-5-(2-nitrophenyl)-4,5-dihydroisoxazole-2-oxide (7a).



A yellow solid; mp 115-117°C; IR [KBr, cm⁻¹]: 3077, 2863, 1646, 1606, 1528, 1351, 1263; ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, *J* = 8.2 Hz, 1H), 7.72 (t, *J* = 7.4


Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 6.83 (t, J = 2.5 Hz, 1H), 5.13 (m, 2H), 2.11 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 147.9, 144.7, 134.4, 133.8, 129.9, 128.7, 125.2, 115.6, 106.8, 75.7, 8.9; MS m/z (relative intensity): 235 (M^+ +1, 11), 234 (M^+ , 100), 203 (5), 187 (17), 171 (5), 158 (38), 130 (33), 103 (45), 93 (14), 79 (36), 76 (23); HRMS calcd for $\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}_4$ (M^+): 234.0635, found 234.0639.

3-(3-nitrophenyl)-3,3a,4,5,6,7-hexahydrobenzo[c]isoxazole-1-oxide (anti) (8a).




A colorless solid; mp 152-154°C; IR [KBr, cm^{-1}]: 3080, 2930, 2855, 1655, 1532, 1345, 1270, 1236; ^1H NMR (400 MHz, CDCl_3): δ 8.24 (s, 1H), 8.18 (d, J = 8.1 Hz, 1H), 7.74 (d, J = 7.6 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 5.20 (d, J = 9.4 Hz, 1H), 3.19-3.13 (m, 1H), 2.81 (dd, J = 15.7, 4.3 Hz, 1H), 2.22-2.14 (m, 2H), 1.99-1.90 (m, 2H), 1.56-1.41 (m, 2H), 1.40-1.27 (m 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 148.6, 140.2, 132.1, 130.2, 123.8, 121.1, 116.7, 82.4, 51.6, 30.9, 24.0, 23.9, 23.6; MS m/z (relative intensity): 262 (M^+ , 52), 245 (45), 170 (1), 150 (15), 111 (28), 81 (100); HRMS calcd for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_4$ (M^+): 262.0948, found 262.0960.

3-(3-nitrophenyl)-3,3a,4,5,6,7-hexahydrobenzo[c]isoxazole-1-oxide (syn) (9a).



A colorless gummy solid; IR [KBr, cm^{-1}]: 2934, 2860, 1703, 1661, 1530, 1448, 1350, 1282, 1231; ^1H NMR (400 MHz, CDCl_3): δ 8.18 (d, J = 8.2 Hz, 1H), 8.14 (s, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.60 (t, J = 7.9 Hz, 1H), 5.82 (d, J = 10.2 Hz, 1H), 3.70-3.62 (m, 1H), 2.88-2.83 (m, 1H), 2.25-2.18 (m, 1H), 1.92-1.88 (m, 1H), 1.80-1.73 (m, 1H), 1.55-1.50 (m, 1H), 1.32-1.19 (m, 2H), 0.76-0.66 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 148.6, 138.9, 131.9, 130.1, 123.5, 121.1, 115.4, 77.2, 47.9, 28.4, 24.4, 24.1, 24.0.


3-(3-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (anti) (10a).



A pale yellow solid; mp 101-103°C; IR [KBr, cm^{-1}]: 3077, 2930, 2856, 1639, 1532, 1451, 1347, 1274, 1241, 1211; ^1H NMR (400 MHz, CDCl_3): δ 8.27 (s, 1H), 8.25 (d, J =


8.2 Hz, 1H), 7.80 (d, J = 7.7 Hz, 1H), 7.62 (t, J = 7.9 Hz, 1H), 5.16 (d, J = 8.1 Hz, 1H), 3.35-3.30 (m, 1H), 2.70-2.65 (m, 1H), 2.57-2.49 (m, 1H), 2.04-1.92 (m, 4H), 1.79-1.68 (m, 1H), 1.52-1.34 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 148.7, 140.6, 132.2, 130.3, 123.9, 121.3, 120.3, 81.6, 55.5, 32.9, 30.2, 28.9, 27.7, 25.3; MS m/z (relative intensity): 276 (M^+ , 37), 259 (25), 176 (2), 150 (11), 125 (13), 95 (100); HRMS calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_4$ (M^+): 276.1105, found 276.1114.

3-(3-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (*syn*) (11a).




A pale yellow solid; mp 105-107°C; IR [KBr, cm^{-1}]: 2930, 2856, 1639, 1532, 1451, 1351, 1277, 1218, 1203; ^1H NMR (400 MHz, CDCl_3): δ 8.21 (d, J = 8.2 Hz, 1H), 8.18 (s, 1H), 7.71 (d, J = 7.7 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 5.77 (d, J = 9.0 Hz, 1H), 3.64-3.59 (m, 1H), 2.74-2.69 (m, 1H), 2.58-2.49 (m, 1H), 2.05-1.94 (m, 2H), 1.82-1.79 (m, 1H), 1.50-1.47 (m, 1H), 1.30-1.26 (m, 1H), 1.22-1.13 (m, 2H), 1.12-1.05 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 148.5, 137.6, 132.5, 130.0, 123.6, 121.6, 120.8, 79.0, 50.4, 30.2, 29.6, 29.1, 27.5, 25.3; MS m/z (relative intensity): 276 (M^+ , 39), 259 (20), 231 (4), 176 (3), 150 (9), 125 (14), 95 (100), 67 (17); HRMS calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_4$ (M^+) 276.1105, found 276.1112.

3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9-octahydrocycloocta[c]isoxazole-1-oxide (*anti*) (12a).




A colorless solid; mp 98-100 °C; IR [KBr, cm^{-1}]: 3085, 2922, 2863, 1635, 1532, 1462, 1347, 1292; ^1H NMR (400 MHz, CDCl_3): δ 8.24-8.22 (m, 2H), 7.80 (d, J = 7.7 Hz, 1H), 7.61 (t, J = 8.6 Hz, 1H), 5.29 (d, J = 6.8 Hz, 1H), 3.30 (dd, J = 11.5, 7.2 Hz, 1H), 2.76-2.69 (m, 1H), 2.34-2.27 (m, 1H), 2.09-2.05 (m, 1H), 1.92-1.84 (m, 4H), 1.71-1.66 (m, 2H), 1.63-1.57 (m, 1H), 1.55-1.42 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 148.8, 141.3, 131.7, 130.3, 123.8, 120.8, 119.2, 79.9, 53.9, 29.2, 26.3, 25.6, 25.5, 24.0, 23.6; MS m/z (relative intensity): 290 (M^+ , 44), 273 (14), 244 (5), 162 (3), 150 (9), 109 (100), 67 (57); HRMS calcd for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_4$ (M^+): 290.1261, found 290.1269.

3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9-octahydrocycloocta[c]isoxazole-1-oxide (syn) (13a).




A pale yellow solid; mp 130-132 °C; IR [KBr, cm⁻¹]: 3092, 2929, 2858, 1630, 1529, 1463, 1443, 1349; ¹H NMR (400 MHz, CDCl₃): δ 8.22 (d, *J* = 7.3 Hz, 1H), 8.20 (s, 1H), 7.73 (d, *J* = 7.7 Hz, 1H), 7.62-7.58 (m, 1H), 5.82 (d, *J* = 7.9 Hz, 1H), 3.45-3.39 (m, 1H), 2.68-2.58 (m, 2H), 2.04-1.99 (m, 1H), 1.72-1.61 (m, 2H), 1.58-1.46 (m, 3H), 1.32-1.26 (m, 3H), 1.18-1.11 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 148.5, 136.9, 132.3, 129.9, 123.5, 121.9, 121.4, 80.3, 48.9, 28.7, 27.5, 26.1, 25.9, 23.9, 22.7; MS m/z (relative intensity): 290 (M⁺, 39), 273 (48), 150 (100), 109 (65); HRMS calcd for C₁₅H₁₈N₂O₄ (M⁺): 290.1267, found 290.1262.

3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9,10,11,12,13-dodecahydrocyclododeca[c]isoxazole-1-oxide (anti) (14a).



A colorless solid; mp 113-115 °C; IR [KBr, cm⁻¹]: 2932, 2863, 1637, 1531, 1469, 1444, 1351; ¹H NMR (400 MHz, CDCl₃): δ 8.22-8.20 (m, 2H), 7.76 (d, *J* = 7.7 Hz, 1H), 7.63-7.58 (m, 1H), 5.29 (d, *J* = 5.6 Hz, 1H), 3.32 (dd, *J* = 10.0, 4.8 Hz, 1H), 2.53-2.46 (m, 1H), 2.43-2.36 (m, 1H), 1.94-1.75 (m, 3H), 1.61-1.46 (m, 5H), 1.46-1.25 (m, 10H); ¹³C NMR (100 MHz, CDCl₃): δ 148.8, 142.2, 131.5, 130.4, 123.8, 120.6, 117.2, 79.3, 54.6, 29.7, 25.7, 25.1, 24.3, 24.2, 23.6, 23.3, 23.2, 22.3; MS m/z (relative intensity): 346 (M⁺, 100), 329 (53), 299 (34), 230 (5), 216 (9), 202 (14), 163 (23), 150 (15), 95 (30), 83 (55); HRMS calcd for C₁₉H₂₆N₂O₄ (M⁺): 346.1893, found 346.1885.


3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9,10,11,12,13-dodecahydrocyclododeca[c]isoxazole-1-oxide (syn) (15a).



A colorless solid; mp 118-120 °C; IR [KBr, cm⁻¹]: 3091, 2934, 2864, 1651, 1634, 1538, 1531, 1469, 1445, 1348; ¹H NMR (400 MHz, CDCl₃): δ 8.23-8.20 (m, 2H), 7.72 (d, *J* = 7.7 Hz, 1H), 7.61 (t, *J* = 7.8 Hz, 1H), 5.79 (d, *J* = 8.6 Hz,


1H), 3.59 (dd, $J = 13.6, 5.8$ Hz, 1H), 2.63-2.55 (m, 1H), 2.47-2.40 (m, 1H), 1.76-1.70 (m, 1H), 1.68-1.62 (m, 1H), 1.53-1.47 (m, 2H), 1.43-1.35 (m, 7H), 1.29-1.20 (m, 4H), 1.18-1.11 (m, 2H), 1.01-0.97 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 148.5, 137.2, 132.4, 129.9, 123.6, 121.6, 120.4, 79.1, 48.2, 25.9, 25.8, 24.5, 24.2, 23.7, 23.6, 23.4, 22.9, 22.8; MS m/z (relative intensity): 346 (M^+ , 100), 329 (77), 298 (11), 228 (3), 222 (8), 178 (11), 163 (20), 95 (30), 83 (61); HRMS calcd for $\text{C}_{19}\text{H}_{26}\text{N}_2\text{O}_4$ (M^+): 346.1893, found 346.1885.

3-(4-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (anti) (16a).




A colorless solid; mp 135-137 °C; IR [KBr, cm^{-1}]: 3079, 2928, 2855, 1640, 1607, 1521, 1451, 1349, 1275; ^1H NMR (400 MHz, CDCl_3): δ 8.28-8.25 (m, 2H), 7.62-7.59 (m, 2H), 5.16 (d, $J = 7.8$ Hz, 1H), 3.30-3.25 (m, 1H), 2.67-2.62 (m, 1H), 2.57-2.49 (m, 1H), 1.99-1.91 (m, 4H), 1.79-1.70 (m, 1H), 1.47-1.40 (m, 1H), 1.36-1.32 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 148.4, 145.7, 126.9, 124.4, 120.1, 81.5, 55.6, 33.2, 30.1, 28.9, 27.7, 25.3; MS m/z (relative intensity): 276 (M^+ , 39), 259 (6), 230 (2), 176 (2), 125 (14), 95 (100), 67 (10); HRMS calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_4$ (M^+): 276.1105, found 276.1111.

3-(4-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (syn) (17a).




A colorless solid; mp 95-97 °C; IR [KBr, cm^{-1}]: 3079, 2929, 2855, 1640, 1606, 1519, 1451, 1382, 1348, 1278; ^1H NMR (400 MHz, CDCl_3): δ 8.25 (d, $J = 8.6$ Hz, 2H), 7.51 (d, $J = 8.6$ Hz, 2H), 5.75 (d, $J = 9.0$ Hz, 1H), 3.65-3.59 (m, 1H), 2.73-2.68 (m, 1H), 2.57-2.48 (m, 1H), 2.03-1.94 (m, 2H), 1.81-1.78 (m, 1H), 1.53-1.44 (m, 1H), 1.29-1.21 (m, 1H), 1.16 (dd, $J = 22.6, 11.4$ Hz, 2H), 1.10-0.99 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 148.2, 142.7, 127.5, 124.0, 120.7, 79.0, 50.5, 30.1, 29.6, 29.2, 27.5, 25.3; MS m/z (relative intensity): 276 (M^+ , 46), 259 (16), 184 (5), 150 (8), 125 (14), 95 (100), 67 (13); HRMS calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_4$ (M^+): 276.1105, found 276.1102.

3-methyl-5-(4-nitrophenyl)-4,5-dihydroisoxazole-2-oxide (18a).




A colorless solid; mp 123-125 °C; IR [KBr, cm^{-1}]: 3107, 2922, 2849, 1653, 1598, 1513, 1351; ^1H NMR (400 MHz, CDCl_3): δ 8.28 (d, $J = 8.5$ Hz, 2H), 7.58 (d, $J = 8.5$ Hz, 2H), 5.69 (dd, $J = 9.4, 7.1$ Hz, 1H), 3.63 (dd, $J = 17.0, 9.8$ Hz, 1H), 3.03 (dd, $J = 17.0, 6.6$ Hz, 1H), 2.04 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 148.3, 146.6, 126.4, 124.5, 111.1, 73.9, 42.5, 11.9; MS m/z (relative intensity): 223 (M^++1 , 23), 222 (M^+ , 100), 205 (7), 175 (18), 150 (44), 146 (7), 84 (4), 71 (39), 55 (7); HRMS calcd for $\text{C}_{10}\text{H}_{10}\text{N}_2\text{O}_4$ (M^+): 222.0635, found 222.0644.

5-(2-(allyloxy)-5-nitrophenyl)-3-methyl-4,5-dihydroisoxazole-2-oxide (19a).




A yellow solid; mp 85-87 °C; IR [KBr, cm^{-1}]: 3086, 2923, 1659, 1652, 1613, 1593, 1520, 1488, 1338, 1271; ^1H NMR (400 MHz, CDCl_3): δ 8.43 (d, $J = 2.7$ Hz, 1H), 8.22 (dd, $J = 9.0, 2.8$ Hz, 1H), 6.98 (d, $J = 9.1$ Hz, 1H), 6.09-5.99 (m, 1H), 5.81 (dd, $J = 10.0, 2.8$ Hz, 1H), 5.45-5.37 (m, 2H), 4.74-4.65 (m, 2H), 3.65-3.57 (m, 1H), 3.00-2.94 (m, 1H), 2.01 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 159.9, 141.7, 131.6, 129.4, 125.8, 122.1, 119.3, 111.9, 111.7, 70.6, 70.0, 41.3, 11.9; MS m/z (relative intensity): 278 (M^+ , 5), 261 (8), 221 (7), 209 (11), 206 (100), 191 (39), 166 (20), 96 (10), 73 (8); HRMS calcd for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_5$ (M^+): 278.0897, found 278.0887.

3,5-diphenyl-4,5-dihydroisoxazole-2-oxide (20a).




A colorless solid; mp 76-78 °C; IR [KBr, cm^{-1}]: 3048, 2937, 1613, 1591, 1498, 1447, 1384, 1226; ^1H NMR (400 MHz, CDCl_3): δ 7.93 (d, $J = 7.7$ Hz, 2H), 7.46-7.35 (m, 8H), 5.73 (t, $J = 8.5$ Hz, 1H), 3.92 (dd, $J = 16.2, 9.5$ Hz, 1H), 3.55 (dd, $J = 16.2, 7.7$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 138.9, 129.7, 129.2, 129.1, 128.9, 126.9, 126.4, 125.9, 114.1, 75.9, 40.5; MS m/z (relative intensity): 239 (M^+ , 100), 192 (10), 117 (4), 105 (12), 103 (18); HRMS calcd for $\text{C}_{15}\text{H}_{13}\text{N}_1\text{O}_2$ (M^+): 239.0941, found 239.0944.

3-methyl-5-(pyridin-2-yl)-4,5-dihydroisoxazole-2-oxide (21a).




A brown oil; IR [KBr, cm⁻¹]: 3057, 3012, 2922, 1713, 1652, 1593, 1573, 1475, 1438, 1395, 1352, 1259; ¹H NMR (400 MHz, CDCl₃): δ 8.59 (d, *J* = 4.2 Hz, 1H), 7.76 (t, *J* = 7.6 Hz, 1H), 7.61 (d, *J* = 7.8 Hz, 1H), 7.29-7.26 (m, 1H), 5.64 (dd, *J* = 9.9, 5.4 Hz, 1H), 3.63-3.56 (m, 1H), 3.39 (dd, *J* = 17.4, 4.0 Hz, 1H), 2.01 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 158.4, 149.8, 137.4, 123.6, 120.6, 112.4, 74.9, 40.3, 11.9.

3-methyl-4-(2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (22a).




A yellow solid; mp 128-130 °C; IR [KBr, cm⁻¹]: 1641, 1595, 1509, 1361, 1269; ¹H NMR (400 MHz, CDCl₃): δ 8.04 (dd, *J* = 8.2, 1.1 Hz, 1H), 7.66-7.62 (m, 1H), 7.47-7.43 (m, 1H), 7.27 (d, *J* = 7.6, 1H), 6.78 (t, *J* = 3.1 Hz, 1H), 5.29 (d, *J* = 3.1 Hz, 2H), 2.16 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 148.2, 138.5, 133.5, 130.4, 128.8, 128.5, 125.6, 117.5, 113.6, 68.3, 9.1; MS m/z (relative intensity): 235 (M⁺+1, 12), 234 (M⁺, 100), 158 (15), 146 (11), 130 (11), 119 (22), 104 (6), 92 (36); HRMS calcd for C₁₁H₁₀N₂O₄ (M⁺): 234.0635, found 234.0640.

3-methyl-4-(5-chloro-2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (23a).




A yellow solid; mp 129-131 °C; IR [KBr, cm⁻¹]: 3109, 3070, 2923, 1644, 1600, 1578, 1517, 1334, 1279; ¹H NMR (400 MHz, CDCl₃): δ 8.03 (d, *J* = 8.8 Hz, 1H), 7.41 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.22 (d, *J* = 1.7 Hz, 1H), 6.74 (t, *J* = 3.0 Hz, 1H), 5.31 (d, *J* = 3.0 Hz, 2H), 2.15 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 146.3, 139.9, 139.8, 132.4, 128.6, 128.4, 127.2, 117.4, 112.4, 68.1, 9.2; MS m/z (relative intensity): 270 (M⁺+2, 25), 268 (M⁺, 100), 208 (6), 192 (20), 153 (38), 125 (46), 90 (6), 55 (6); HRMS calcd for C₁₁H₉ClN₂O₄ (M⁺): 268.0245, found 268.0257 and calcd for C₁₁H₉³⁷ClN₂O₄ (M⁺): 270.0216, found 270.0225.

3-methyl-4-(5-bromo-2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (24a).




A yellow solid; mp 125-127 °C; IR [KBr, cm⁻¹]: 3092, 3070, 1642, 1580, 1517, 1336, 1274; ¹H NMR (400 MHz, CDCl₃): δ 7.92 (d, *J* = 8.8 Hz, 1H), 7.56 (dd, *J* = 8.7, 1.9 Hz, 1H), 7.39 (d, *J* = 1.7 Hz, 1H), 6.73 (t, *J* = 3.1 Hz, 1H), 5.30 (d, *J* = 3.1 Hz, 2H), 2.15 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 146.8, 139.8, 132.4, 131.6, 131.4, 128.4, 127.2, 117.4, 112.3, 68.1, 9.2; MS m/z (relative intensity): 314 (M⁺+2, 81), 312 (M⁺, 100), 297 (3), 266 (8), 210 (36), 199 (52), 171 (72), 145 (13), 130 (7), 90 (18), 55 (13); HRMS calcd for C₁₁H₉BrN₂O₄ (M⁺): 311.9740, found 311.9745 and calcd for C₁₁H₉⁸¹BrN₂O₄ (M⁺): 313.9720, found 313.9728.

3-methyl-4-(4-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (25a).




A yellow solid; mp 184-186 °C; IR [KBr, cm⁻¹]: 1635, 1603, 1570, 1508, 1340, 1273; ¹H NMR (400 MHz, CDCl₃): δ 8.27 (d, *J* = 8.8 Hz, 2H), 7.27 (d, *J* = 8.8 Hz, 2H), 6.38 (t, *J* = 3.1 Hz, 1H), 5.44 (d, *J* = 3.0 Hz, 2H), 2.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 146.3, 142.1, 139.1, 128.8, 124.6, 117.6, 116.5, 69.0, 9.2; MS m/z (relative intensity): 235 (M⁺+1, 11), 234 (M⁺, 100), 205 (5), 176 (8), 150 (5), 130 (4), 84 (5); HRMS calcd for C₁₁H₁₀N₂O₄ (M⁺): 234.0635, found 234.0643.

3-methylbenzo[d]isoxazole-2-oxide (26a).




A colorless solid; mp 81-83°C; IR [KBr, cm⁻¹]: 1599, 1588, 1457, 1406, 1297, 1217; ¹H NMR (400 MHz, CDCl₃): δ 7.51-7.45 (m, 1H), 7.44 (d, *J* = 7.7 Hz, 1H), 7.31-7.26 (m, 1H), 7.18 (d, *J* = 8.2 Hz, 1H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 150.3, 128.8, 124.1, 121.4, 119.3, 116.4, 107.2, 9.5; MS m/z (relative intensity): 149 (M⁺, 100), 134 (1), 121 (4), 119 (16), 105 (2), 92 (2), 91 (70); HRMS calcd for C₈H₇NO₂ (M⁺): 149.0471, found 149.0477.

6-methoxy-3-methylbenzo[d]isoxazole-2-oxide (27a).




A colorless solid; mp 113-115 °C; IR [KBr, cm⁻¹]: 2974, 2834, 1599, 1504, 1427; ¹H NMR (400 MHz, CDCl₃): δ 7.29 (d, *J* = 8.5 Hz, 1H), 6.88 (dd, *J* = 8.6, 2.2 Hz, 1H), 6.72 (d, *J* = 2.1 Hz, 1H), 3.86 (s, 3H), 2.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 161.7, 151.6, 119.9, 116.3, 113.8, 112.9, 92.2, 55.9, 9.5; MS m/z (relative intensity): 179 (M⁺, 100), 150 (4), 149 (54), 121 (52), 91 (5), 77 (4); HRMS calcd for C₉H₉NO₃ (M⁺): 179.0577, found 179.0587.

5-chloro-3-methylbenzo[d]isoxazole-2-oxide (28a).




A colorless solid; mp 105-107 °C; IR [KBr, cm⁻¹]: 1599, 1582, 1456, 1271, 1211; ¹H NMR (400 MHz, CDCl₃): δ 7.44 (d, *J* = 8.7 Hz, 1H), 7.39 (s, 1H), 7.12 (d, *J* = 8.6 Hz, 1H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 148.5, 129.8, 128.8, 122.8, 118.9, 115.6, 108.3, 9.5; MS m/z (relative intensity): 183 (M⁺, 100), 157 (2), 155 (7), 142 (1), 127 (21), 125 (74), 118 (7), 99 (3), 89 (6); HRMS calcd for C₈H₆NO₂Cl (M⁺): 183.0082, found 183.0089.

Bisisoxazoline-N-oxide derivative (29a).




A colorless solid; mp 176-178 °C; IR [KBr, cm⁻¹]: 1599, 1582, 1456, 1271, 1211; ¹H NMR (400 MHz, CDCl₃): δ 7.37 (s, 1H), 7.03 (d, *J* = 0.4 Hz, 1H), 2.48 (s, 6H); ¹³C NMR (100 MHz, DMSO): δ 150.2, 117.9, 115.2, 111.5, 86.9, 9.1; MS m/z (relative intensity): 220 (M⁺, 100), 190 (9), 148 (13), 131 (16), 122(13); HRMS calcd for C₁₀H₈N₂O₄ (M⁺): 220.0484, found 220.0483.

(2Z)-3-(methylimino)-2-(2-nitrobenzylidene)butanal (33).



The product, a yellow solid, was obtained as a non-separable mixture of *syn* and *anti* oximes in a ratio 2:1; mp 130-132 °C; IR [KBr, cm⁻¹]: 3276, 2922, 2849, 1686, 1522, 1342; ¹H NMR (400 MHz, CDCl₃): δ (for major peaks) 9.76 (s, 1H), 8.20 (d, *J* = 8.2 Hz, 1H), 7.99 (s, 1H), 7.87 (s, 1H), 7.69 (dd, *J* = 16.2, 7.36 Hz, 1H), 7.65-7.56 (m, 1H), 7.41 (d, *J* = 7.6 Hz, 1H), 1.89 (s, 3H) and δ (for minor peaks) 9.76 (s, 1H), 8.27 (d, *J* = 8.1 Hz, 1H), 7.99 (s, 1H), 7.98 (s, 1H), 7.69 (dd, *J* = 16.2, 7.36 Hz, 1H), 7.65-7.56 (m, 1H), 7.41 (d, *J* = 7.6 Hz, 1H), 2.18 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (for major peaks) 191.8, 151.6, 147.5, 147.4, 139.5, 134.1, 133.3, 130.6, 129.9, 125.2, 13.1 and δ (for minor peaks) 190.5, 154.7, 147.4, 143.3, 137.5, 133.8, 133.3, 130.9, 129.9, 125.6, 15.1; MS m/z (relative intensity): 233 (M⁺-1, 14), 205 (44), 170 (55), 130 (100), 103 (92); HRMS calcd for C₁₁H₉N₂O₄ (M⁺-1): 233.0562, found 233.0563.

3-(hydroxyimino)-2-(2-nitrobenzylidene)butylidene-5,5-dimethylcyclohexane-1,3-dione (34).




A yellow solid; mp 212-214 °C; IR [KBr, cm⁻¹]: 3284, 2959, 2871, 1630, 1590, 1531, 1399, 1359, 1264; ¹H NMR (400 MHz, CDCl₃): δ 7.81 (d, *J* = 7.7 Hz, 1H), 7.51-7.43 (m, 3H), 7.35 (d, *J* = 7.5 Hz, 1H), 7.16 (s, 2H), 2.35-2.17 (m, 4H), 2.09 (s, 3H), 1.03 (s, 3H), 0.97 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 194.9, 171.5, 153.8, 149.3, 132.9, 129.8, 129.1, 124.6, 122.9, 118.9, 110.9, 72.4, 50.5, 42.1, 32.6, 29.3, 27.6, 9.5; MS m/z (relative intensity): 358 (M⁺+2, 2), 356 (M+, 56), 339 (66), 293 (64), 292 (45), 280 (16), 235 (5), 222 (30), 188 (35), 169 (100), 158 (43), 83 (16); HRMS calcd for C₁₉H₂₀N₂O₅ (M⁺): 356.1372, found 356.1376.

4. X-ray crystallographic structures

5.1. X-ray crystallographic structure of 1a

CCDC number of the crystal 792924




Crystal data and structure refinement for 1a

Identification code	a9342
Empirical formula	C13 H12 N2 O4
Formula weight	260.25
Temperature	200(2) K
Wavelength	0.71073 Å
Crystal system	Monoclinic
Space group	P 21/n
Unit cell dimensions	$a = 8.7484(2)$ Å $\alpha = 90^\circ$. $b = 14.5938(4)$ Å $\beta = 108.899(2)^\circ$. $c = 9.8507(2)$ Å $\gamma = 90^\circ$.
Volume	1189.86(5) Å ³
Z	4
Density (calculated)	1.453 Mg/m ³
Absorption coefficient	0.110 mm ⁻¹
F(000)	544
Crystal size	0.60 x 0.55 x 0.28 mm ³
Theta range for data collection	2.59 to 25.02°.
Index ranges	-10≤h≤10, -17≤k≤17, -10≤l≤11
Reflections collected	8598
Independent reflections	2071 [R(int) = 0.0260]
Completeness to theta = 25.02°	98.3 %
Absorption correction	multi-scan
Max. and min. transmission	0.9699 and 0.9371

Refinement method	Full-matrix least-squares on F^2
Data / restraints / parameters	2071 / 0 / 172
Goodness-of-fit on F^2	1.135
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0469$, $wR_2 = 0.1391$
R indices (all data)	$R_1 = 0.0606$, $wR_2 = 0.1574$
Largest diff. peak and hole	0.499 and -0.468 e. \AA^{-3}

5.2. X-ray crystallographic structure of 10a

CCDC number of the crystal 792922




Crystal data and structure refinement for 10a.

Identification code	a10697
Empirical formula	C ₁₄ H ₁₆ N ₂ O ₄
Formula weight	276.29
Temperature	200(2) K
Wavelength	0.71073 \AA
Crystal system	Monoclinic
Space group	P 21/c
Unit cell dimensions	$a = 6.74(2) \text{\AA}$ $\alpha = 90^\circ$. $b = 12.46(4) \text{\AA}$ $\beta = 91.77(7)^\circ$. $c = 15.25(5) \text{\AA}$ $\gamma = 90^\circ$.

Volume	1281(7) Å ³
Z	4
Density (calculated)	1.433 Mg/m ³
Absorption coefficient	0.106 mm ⁻¹
F(000)	584
Crystal size	0.55 x 0.08 x 0.02 mm ³
Theta range for data collection	2.67 to 24.26°.
Index ranges	-7<=h<=5, -14<=k<=13, -5<=l<=17
Reflections collected	4392
Independent reflections	1714 [R(int) = 0.2833]
Completeness to theta = 24.26°	82.6 %
Absorption correction	multi-scan
Max. and min. transmission	0.9979 and 0.9439
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	1714 / 0 / 181
Goodness-of-fit on F ²	1.116
Final R indices [I>2sigma(I)]	R1 = 0.1771, wR2 = 0.3848
R indices (all data)	R1 = 0.2822, wR2 = 0.4406
Largest diff. peak and hole	0.791 and -0.639 e.Å ⁻³

5.3 X-ray crystallographic structure of 11a

CCDC number of the crystal 792920




Crystal data and structure refinement for 11a.

Identification code	10908	
Empirical formula	C ₁₄ H ₁₆ N ₂ O ₄	
Formula weight	276.29	
Temperature	200(2) K	
Wavelength	0.71073 Å	
Crystal system	Triclinic	
Space group	P -1	
Unit cell dimensions	a = 6.3130(2) Å b = 10.4530(3) Å c = 20.3210(7) Å	α = 90.0380(10)°. β = 90.0260(10)°. γ = 90.037(2)°.
Volume	1340.98(7) Å ³	
Z	4	
Density (calculated)	1.369 Mg/m ³	
Absorption coefficient	0.101 mm ⁻¹	
F(000)	584	
Crystal size	0.4 x 0.35 x 0.3 mm ³	
Theta range for data collection	2.19 to 25.06°.	
Index ranges	-7<=h<=7, -10<=k<=12, -23<=l<=24	
Reflections collected	9089	
Independent reflections	4521 [R(int) = 0.0389]	
Completeness to theta = 25.06°	95.9 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.9957 and 0.9336	

Refinement method	Full-matrix least-squares on F^2
Data / restraints / parameters	4521 / 0 / 361
Goodness-of-fit on F^2	1.062
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0431$, $wR_2 = 0.1232$
R indices (all data)	$R_1 = 0.0632$, $wR_2 = 0.1461$
Largest diff. peak and hole	0.323 and -0.431 e. \AA^{-3}

5.4. X-ray crystallographic structure of 14a

CCDC number of the crystal 792923




Crystal data and structure refinement for 14a.

Identification code	a11044
Empirical formula	C19 H26 N2 O4
Formula weight	346.42
Temperature	200(2) K
Wavelength	0.71073 \AA
Crystal system	Triclinic
Space group	P -1
Unit cell dimensions	$a = 7.5626(3) \text{\AA}$ $\alpha = 108.6670(10)^\circ$. $b = 10.9151(3) \text{\AA}$ $\beta = 98.9220(10)^\circ$. $c = 11.7483(3) \text{\AA}$ $\gamma = 100.8220(10)^\circ$.

Volume	877.97(5) Å ³
Z	2
Density (calculated)	1.310 Mg/m ³
Absorption coefficient	0.092 mm ⁻¹
F(000)	372
Crystal size	0.68 x 0.48 x 0.20 mm ³
Theta range for data collection	1.88 to 25.03°.
Index ranges	-8<=h<=4, -12<=k<=12, -13<=l<=13
Reflections collected	6336
Independent reflections	3000 [R(int) = 0.0241]
Completeness to theta = 25.03°	97.4 %
Absorption correction	multi-scan
Max. and min. transmission	0.9818 and 0.9401
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	3000 / 0 / 221
Goodness-of-fit on F ²	1.599
Final R indices [I>2sigma(I)]	R1 = 0.0571, wR2 = 0.1653
R indices (all data)	R1 = 0.0671, wR2 = 0.1785
Largest diff. peak and hole	0.667 and -0.559 e.Å ⁻³

5.5. X-ray crystallographic structure of 15a

CCDC number of the crystal 792921




Crystal data and structure refinement for 15a.

Identification code	11043	
Empirical formula	C ₁₉ H ₂₆ N ₂ O ₄	
Formula weight	346.42	
Temperature	293(2) K	
Wavelength	0.71073 Å	
Crystal system	Monoclinic	
Space group	P 21/n	
Unit cell dimensions	a = 13.0697(3) Å	α = 90°.
	b = 7.7190(2) Å	β = 98.0780(10)°.
	c = 18.1460(5) Å	γ = 90°.
Volume	1812.50(8) Å ³	
Z	4	
Density (calculated)	1.270 Mg/m ³	
Absorption coefficient	0.089 mm ⁻¹	
F(000)	744	
Crystal size	0.66 x 0.58 x 0.4 mm ³	
Theta range for data collection	2.06 to 25.04°.	
Index ranges	-15<=h<=15, -9<=k<=8, -20<=l<=21	
Reflections collected	9668	
Independent reflections	3206 [R(int) = 0.0688]	
Completeness to theta = 25.04°	99.7 %	
Absorption correction	Semi-empirical from equivalents	

Max. and min. transmission	1.2356 and 0.8163
Refinement method	Full-matrix least-squares on F^2
Data / restraints / parameters	3206 / 0 / 226
Goodness-of-fit on F^2	1.075
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0816$, $wR_2 = 0.2280$
R indices (all data)	$R_1 = 0.1106$, $wR_2 = 0.2584$
Largest diff. peak and hole	0.587 and -0.444 e. \AA^{-3}

5.6. X-ray crystallographic structure of 23a

CCDC number of the crystal 792919




Crystal data and structure refinement for 23a.

Identification code	10377
Empirical formula	C11 H9 Cl N2 O4
Formula weight	268.65
Temperature	293(2) K
Wavelength	0.71073 \AA


Crystal system	Triclinic
Space group	P -1
Unit cell dimensions	a = 7.6607(3) Å b = 7.7335(3) Å c = 10.9132(4) Å
	α= 106.496(2)°. β= 96.783(2)°. γ = 106.600(2)°.
Volume	579.96(4) Å ³
Z	2
Density (calculated)	1.538 Mg/m ³
Absorption coefficient	0.338 mm ⁻¹
F(000)	276
Crystal size	0.37 x 0.31 x 0.25 mm ³
Theta range for data collection	2.84 to 25.05°.
Index ranges	-9<=h<=9, -9<=k<=9, -12<=l<=12
Reflections collected	4143
Independent reflections	2028 [R(int) = 0.0363]
Completeness to theta = 25.05°	99.0 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.9699 and 0.8014
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	2028 / 0 / 163
Goodness-of-fit on F ²	1.005
Final R indices [I>2sigma(I)]	R1 = 0.0443, wR2 = 0.1180
R indices (all data)	R1 = 0.0509, wR2 = 0.1239
Largest diff. peak and hole	0.285 and -0.258 e.Å ⁻³

5. ^1H and ^{13}C NMR spectra


3-(2-nitrophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (1a): ^1H NMR (400 MHz, CDCl_3)




3-(2-nitrophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (1a): ^{13}C NMR (100 MHz, CDCl_3)




3-(2-nitrophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (1a): Cosy (400 MHz, CDCl₃)




3-(2-nitrophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (1a): HMQC (500 MHz, CDCl₃)




3-(2-nitro-5-chlorophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (2a): ^1H NMR (400 MHz, CDCl_3)




3-(2-nitro-5-chlorophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (2a): ^{13}C NMR (100 MHz, CDCl_3)




3-(2,4-dichlorophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (3a): ^1H NMR (400 MHz, CDCl_3)




3-(2,4-dichlorophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (3a): ^{13}C NMR (100 MHz, CDCl_3)




3-(2-bromophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (4a): ^1H NMR (400 MHz, CDCl_3)




3-(2-bromophenyl)-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (4a): ^{13}C NMR (100 MHz, CDCl_3)




3-phenyl-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (5a): ^1H NMR (400 MHz, CDCl_3)




3-phenyl-3,5,6,7-tetrahydrobenzo[c]isoxazole-1-oxide (5a): ^{13}C NMR (100 MHz, CDCl_3)




3-methyl-4-methylene-5-(2-nitrophenyl)-4,5-dihydroisoxazole-2-oxide (7a): ^1H NMR (400 MHz, CDCl_3)




3-methyl-4-methylene-5-(2-nitrophenyl)-4,5-dihydroisoxazole-2-oxide (7a): ¹³C NMR (100 MHz, CDCl₃)




3-(3-nitrophenyl)-3,3a,4,5,6,7-hexahydrobenzo[c]isoxazole-1-oxide (anti) (8a): ¹H NMR (400 MHz, CDCl₃)




3-(3-nitrophenyl)-3,3a,4,5,6,7-hexahydrobenzo[c]isoxazole-1-oxide (anti) (8a): ^{13}C NMR (100 MHz, CDCl_3)




3-(3-nitrophenyl)-3,3a,4,5,6,7-hexahydrobenzo[c]isoxazole-1-oxide (syn) (9a): ^1H NMR (400 MHz, CDCl_3)




3-(3-nitrophenyl)-3,3a,4,5,6,7-hexahydrobenzo[c]isoxazole-1-oxide (syn) (9a): ^{13}C NMR (100 MHz, CDCl_3)




3-(3-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (anti) (10a): ^1H NMR (400 MHz, CDCl_3)




3-(3-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (anti) (10a): ^{13}C NMR (100 MHz, CDCl_3)




3-(3-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (syn) (11a) ^1H NMR (400 MHz, CDCl_3)




3-(3-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (syn) (11a) ^{13}C NMR (100 MHz, CDCl_3)




3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9-octahydrocycloocta[c]isoxazole-1-oxide (anti) (12a) ^1H NMR (400 MHz, CDCl_3)




3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9-octahydrocycloocta[c]isoxazole-1-oxide (anti) (12a) ^{13}C NMR
(100 MHz, CDCl_3)




3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9-octahydrocycloocta[c]isoxazole-1-oxide (syn) (13a) ^1H NMR (400 MHz, CDCl_3)




3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9-octahydrocycloocta[c]isoxazole-1-oxide (syn) (13a) ^{13}C NMR (100 MHz, CDCl_3)




3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9,10,11,12,13-dodecahydrocyclododeca[c]isoxazole-1-oxide (anti) (14a) ^1H NMR (400 MHz, CDCl_3)




3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9,10,11,12,13-dodecahydrocyclododeca[c]isoxazole-1-oxide (anti) (14a) ¹³C NMR (100 MHz, CDCl₃)




3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9,10,11,12,13-dodecahydrocyclododeca[c]isoxazole-1-oxide (syn) (15a) ¹H NMR (400 MHz, CDCl₃)




3-(3-nitrophenyl)-3,3a,4,5,6,7,8,9,10,11,12,13-dodecahydrocyclododeca[c]isoxazole-1-oxide (syn) (15a) ^{13}C NMR (100 MHz, CDCl_3)




3-(3-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (anti) (16a) ^1H NMR (400 MHz, CDCl_3)




3-(4-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (anti) (16a) ^{13}C NMR
(100 MHz, CDCl_3)




3-(4-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (syn) (17a) ^1H NMR
(400 MHz, CDCl_3)




3-(3-nitrophenyl)-3a,4,5,6,7,8-hexahydro-3H-cyclohepta[c]isoxazole-1-oxide (syn) (17a) ^{13}C NMR (100 MHz, CDCl_3)




3-methyl-5-(4-nitrophenyl)-4,5-dihydroisoxazole-2-oxide (18a) ^1H NMR (400 MHz, CDCl_3)




3-methyl-5-(4-nitrophenyl)-4,5-dihydroisoxazole-2-oxide (18a) ^{13}C NMR (100 MHz, CDCl_3)




5-(2-(allyloxy)-5-nitrophenyl)-3-methyl-4,5-dihydroisoxazole-2-oxide (19a) ^1H NMR (400 MHz, CDCl_3)




5-(2-(allyloxy)-5-nitrophenyl)-3-methyl-4,5-dihydroisoxazole-2-oxide (19a) ^{13}C NMR (100 MHz, CDCl₃)




3,5-diphenyl-4,5-dihydroisoxazole-2-oxide (20a) ^1H NMR (400 MHz, CDCl₃)




3,5-diphenyl-4,5-dihydroisoxazole-2-oxide (20a) ^{13}C NMR (100 MHz, CDCl_3)




3-methyl-5-(pyridine-2-yl)-4,5-dihydroisoxazole-2-oxide (21a) ^1H NMR (400 MHz, CDCl_3)




3-methyl-5-(pyridine-2-yl)-4,5-dihydroisoxazole-2-oxide (21a) ^{13}C NMR (100 MHz, CDCl_3)




3-methyl-4-(2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (22a) ^1H NMR (400 MHz, CDCl_3)




3-methyl-4-(2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (22a) ^{13}C NMR (100 MHz, CDCl_3)




3-methyl-4-(5-chloro-2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (23a) ^1H NMR (400 MHz, CDCl_3)




3-methyl-4-(5-chloro-2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (23a) ^{13}C NMR (100 MHz, CDCl_3)




3-methyl-4-(5-bromo-2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (24a) ^1H NMR (400 MHz, CDCl_3)




3-methyl-4-(5-bromo-2-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (24a) ^{13}C NMR (100 MHz, CDCl_3)




3-methyl-4-(4-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (25a) ^1H NMR (400 MHz, CDCl_3)




3-methyl-4-(4-nitrobenzylidene)-4,5-dihydroisoxazole-2-oxide (25a) ^{13}C NMR (100 MHz, CDCl_3)




3-methylbenzo[d]isoxazole-2-oxide (26a) ^1H NMR (400 MHz, CDCl_3)




3-methylbenzo[d]isoxazole-2-oxide (26a) ^{13}C NMR (100 MHz, CDCl_3)




6-methoxy-3-methylbenzo[d]isoxazole-2-oxide (27a) ^1H NMR (400 MHz, CDCl_3)




6-methoxy-3-methylbenzo[d]isoxazole-2-oxide (27a) ^{13}C NMR (100 MHz, CDCl_3)




5-chloro-3-methylbenzo[d]isoxazole-2-oxide (28a) ^1H NMR (400 MHz, CDCl_3)




5-chloro-3-methylbenzo[d]isoxazole-2-oxide (28a) ^1H NMR (400 MHz, CDCl_3)




Bisisoxazoline-N-oxide derivative (29a) ^1H NMR (400 MHz, CDCl_3)




Bisisoxazoline-N-oxide derivative (29a) ^{13}C NMR (100 MHz, DMSO)




(2Z)-3-(methylimino)-2-(2-nitrobenzylidene)butanal (33) ^1H NMR (400 MHz, CDCl_3)




(2Z)-3-(methylimino)-2-(2-nitrobenzylidene)butanal (33) ^{13}C NMR (100 MHz, CDCl_3)




3-(hydroxyimino)-2-(2-nitrobenzylidene)butylidene)-5,5-dimethylcyclohexane-1,3-dione (34) ¹H NMR (400 MHz, CDCl₃)



3-(hydroxyimino)-2-(2-nitrobenzylidene)butylidene)-5,5-dimethylcyclohexane-1,3-dione (34) ¹³C NMR (100 MHz, CDCl₃)



6. Spectra related to the ^1H NMR experiment to support the proposed mechanism



Spectra related to the ^1H NMR experiment in D_2O . (a) Immediately after the addition of reagent to the starting material and mild shaking. The doublet at 8.22 ppm, the triplet at 7.76 ppm and the triplet at 7.61 ppm are assigned to PhI^+OH . The deviation in chemical shift values, from our earlier report,^{10a} is due to the difference in the environment around the in situ formed (hydroxyl)phenyliodinium ion. (b) Spectra, after a vigorous shaking with a mechanical shaker. The PhI^+OH peaks have completely disappeared. (c) Spectra of the crude mixture after the ^1H NMR experiment, in CDCl_3 . The doublet at 7.72 ppm, triplet at 7.32 and 7.12 ppm are assigned to iodobenzene. The doublets at 7.52 and 7.51 ppm correspond to the product peak.

References:

- r1. For Baylis-Hillman adducts, please see. (a) Luo, S.; Wang, P. G.; Cheng, J.-P. *J. Org. Chem.* **2004**, 69, 555. (b) Shi, M.; Jiang, J.-K.; Li, C.-Q. *Tetrahedron Lett.* **2002**, 43, 127.

r2. (a) Chimni, S. S.; Mahajan, D. *Tetrahedron* **2005**, *61*, 5019. (b) Dimmock, J. R.; Jha, A.; Kumar, P.; Zello, G. A.; Quail, J. W.; Oloo, E. O.; Oucharek, J. J.; Pasha, M. K.; Seitz, D.; Sharma, R. K.; Allen, T. M.; Santos, C. L.; Manavathu, E. K.; Clercq, E. D.; Balzarini, J.; Stables, J. P. *Eur. J. Med. Chem.* **2002**, *37*, 35.

r3. (a) Lee, K. Y.; Kim, J. M.; Kim, J. N. *Tetrahedron* **2003**, *59*, 385. (b) Kim, H. S.; Kim, T. Y.; Lee, K. Y.; Chung, Y. M.; Lee, H. J.; Kim, J. N. *Tetrahedron Lett.* **2000**, *41*, 2613. (c) Basavaiah, D.; Kumaragurubaran, N.; Padmaja, K. *Synlett.* **1999**, 1630. (d) Unpublished work; to be published.